Reata Pharmaceuticals, Inc. (RETA) insider have most recently took part in a trading activity. On Dec 28, 2017 Traweek James W Jr, 10% Owner bought 27,200 shares having total worth of $705,296 at the price of $25.93 per share, following the transaction a total of 2,923,142 shares owned by Traweek James W Jr. Before this latest buy, Traweek James W Jr purchased RETA at 2 other times during the past twelve months, for a total investment of $51.62M at an average of $23.26 per share.
The stock has experienced a total of 5 insider trades in the past three months. These trades include 5 buy trades. Furthermore, over the past 12 months , the stock was traded 13 times by insiders. In 4 of these trades, the insider was a seller while an employee of the company was the buyer in 9 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Reata Pharmaceuticals, Inc. (RETA) traded down 1.15% on Dec 27, 2017, hitting $25.71. 192,814 shares of the company’s stock traded hands. Reata Pharmaceuticals, Inc. has a 52 week low of $15.51 and a 52 week high of $36.11. The company’s market cap is $0 million.
Reata Pharmaceuticals, Inc. (RETA) last announced its earnings results on Nov 13, 2017. The company reported -0.50 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.41 by $0.09. The company had revenue of $13 million for the quarter, compared to the consensus estimate of $13 million. During the same quarter in the previous year, the company posted -0.04 earnings per share. The company’s revenue for the quarter was up 0% on a year-over-year basis.
|earnings per share||-0.50||-0.52||-0.32||-0.19||-0.04||-0.05|
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018